Nirmatrelvir-Ritonavir (Paxlovid)

Abstract

CADTH recommends that Paxlovid be reimbursed by public drug plans for the treatment of mild to moderate COVID-19 in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death, if certain conditions are met. Paxlovid should only be covered to treat patients who have severe or moderate immunosuppression as described in Table 1. Treatment should be initiated as soon as possible within 5 days of symptom onset. Paxlovid should only be reimbursed if the cost is reduced.